Silencing RSAD2 in B cells from patients with primary Sjögren’s syndrome attenuates their hyperactivation via suppression of the NF-κB pathway, suggesting its potential as a therapeutic target [42]. This evidence concerns the gene RSAD2 and Sjogren syndrome.